Compare Ascendis Pharma A/S (ASND) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Global Clean Energy ETF — how do they compare? Ascendis Pharma A/S trades at $254.19 (market cap $16.67B), while iShares Global Clean Energy ETF trades at $18.46. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | ICLN | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | — |
52-Week High | $277.18 | $23.75 |
52-Week Low | $189.74 | $13.66 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
ICLN trades at $18.69, up 3.37% today, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces headwinds from higher expense ratios compared to traditional energy peers and regulatory uncertainty around renewable energy permits. Recent news highlights clean energy's 25% gains in 2026 but notes volatility concerns versus fossil fuel alternatives.
The outlook remains cautious as policy risks and competitive pressure from lower-cost energy ETFs challenge near-term performance. Long-term growth potential exists from global clean energy adoption, but investors face volatility and fee disadvantages relative to traditional energy funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
